GlassScriptPhysician profile
Leon Ronen
NPI 1922063577
$8,210.65
in general payments reported to CMS, 2019-2025
43 companies · $3,094 in 2025
The $3,094 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $115 · 2021: $762 · 2022: $1,455 · 2023: $1,498 · 2024: $797 · 2025: $3,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,140 · Consulting Fee: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,139.87 |
| Consulting Fee | $1,249.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $1,478.73 | 2025 | |
| Abbvie INC. | $1,472.30 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $983.47 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $539.44 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $444.80 | 2023-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.43 | 2019-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $274.67 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Dexcom, INC. | $242.29 | 2024-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Amgen INC. | $201.11 | 2019-2024 | Otezla, Repatha |
| Lilly USA, LLC | $174.48 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $170.55 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $140.33 | 2019-2025 | |
| Astellas Pharma US INC | $131.75 | 2023-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $130.87 | 2022-2025 | Rexulti |
| Corium, LLC | $126.74 | 2022-2023 | Azstarys |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $124.25 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Teva Pharmaceuticals USA, INC. | $111.73 | 2022-2023 | Austedo, Austedo Xr |
| Lundbeck LLC | $99.94 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $99.49 | 2022-2024 | Auvelity |
| Xeris Pharmaceuticals, INC. | $99.41 | 2022-2025 | Gvoke Hypopen, Keveyis |
| Alkermes, INC. | $97.20 | 2023-2025 | Aristada, Vivitrol, Lybalvi |
| Ironshore Pharmaceuticals INC. | $95.01 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $80.07 | 2022 | |
| Organon LLC | $62.91 | 2024-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $62.13 | 2019-2025 | Capvaxive, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $57.65 | 2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $55.15 | 2019-2025 | Fanapt |
| Medtronic, INC. | $43.09 | 2025 | Inceptiv |
| Shield Therapeutics INC | $37.23 | 2023-2024 | Accrufer |
| Indivior INC. | $37.09 | 2024-2025 | Sublocade |
| Allergan, INC. | $30.10 | 2019-2020 | |
| Sequel Med Tech, LLC | $25.00 | 2025 | Twiist |
| Evoke Pharma, INC. | $23.00 | 2023 | Gimoti |
| Neurocrine Biosciences, INC. | $22.36 | 2024 | Ingrezza |
| Corcept Therapeutics | $21.71 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $20.85 | 2025 | Gemtesa |
| Amarin Pharma, INC. | $15.89 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.42 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.96 | 2022 | |
| Hologic Sales and Service, LLC | $14.90 | 2024 | Aptima, Thinprep 2000 Processor |
| Janssen Pharmaceuticals, INC | $14.67 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.52 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $12.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Ronen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.